Medical/Pharmaceuticals

I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting

SHANGHAI and GAITHERSBURG, Md., Oct. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter "ABL"), a South Kor...

2021-10-05 20:00 9058

RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer

STOCKHOLM, Oct. 5, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onOctober 5, 2021, that it has received and validated the top line results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 20...

2021-10-05 19:14 1181

Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.

MONTREAL, Oct. 5, 2021 /PRNewswire/ -- Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS). Innodem's AI-powere...

2021-10-05 19:04 1194

NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference

SHELTON, Conn., Oct. 5, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, presented an update of its Pan-Coronavirus COVID-19 Drug Development Program at t...

2021-10-05 18:45 10727

Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial

SYDNEY, Oct. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at t...

2021-10-05 18:00 1261

New clinical trial shows 53% reduction of ventilator-associated pneumonia with Bactiguard's endotracheal tube

STOCKHOLM, Oct. 5, 2021 /PRNewswire/ -- This week at the European Society of Intensive Care congress (ESICM), a study from Liège,Belgium on Bactiguard's endotracheal tubes was presented. The study showed a 53% reduction in ventilator-associated pneumonia (VAP) in intensive care patients, intubate...

2021-10-05 14:38 1499

New, Unpublished Data Reveals Impact of COVID-19 in Patients With Neurological Disorders; Renowned Neuroscientist Ettore Beghi Presents Findings in "Special Lecture on Neuro COVID," Oct 4, 2021, World Congress of Neurology 2021

LONDON, Oct. 5, 2021 /PRNewswire/ -- New data for the first time reveals a connection between COVID-19 and its worsening impact on patients with existing neurological conditions. Newly released research identifying distinct profiles of COVID-19 patients with neurological conditions and manifestat...

2021-10-05 14:27 1300

Dr Joshua Loh Shares New and Advanced Percutaneous Coronary Intervention (PCI) Techniques in 2021 to Treat Coronary Heart Disease - a Major Cause of Death in Singapore

SINGAPORE, Oct. 5, 2021 /PRNewswire/ -- According to the Ministry of Health Singapore , coronary heart disease accounted for 20.5% of all deaths inSingapore in 2020. In this article,Dr Joshua Loh

2021-10-05 10:00 1571

Zuellig Pharma Receives EcoVadis Platinum Medal in 2021 For Sustainability

SINGAPORE, Oct. 5, 2021 /PRNewswire/ -- Zuellig Pharma, a leading healthcare services provider inAsia, has been awarded the Platinum Medal 2021 by sustainability ratings specialistEcoVadis . The award is the highest accolade to be awarded to a company for its sustainability...

2021-10-05 09:00 2737

Himalaya Therapeutics Announces Submission in Mainland China of IND Applications for its CAB-AXL-ADC to treat sarcomas and NSCLC, its CAB-ROR2-ADC to treat melanoma and NSCLC

SHANGHAI and SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- Himalaya Therapeutics  ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China, of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, whi...

2021-10-05 01:08 1422

RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the opaganib global Phase 2/3 study in hospitalized patien...

2021-10-04 21:24 9476

Kintor Pharma Announces First Patient Dosing in Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients in US

SUZHOU, China, Oct. 4, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that onOctober 1 its phase III clinical trial of proxalutamide for the ...

2021-10-04 16:30 9639

Debiopharm Encourages Breakthrough Cancer Research in Japan Through its Competitive JCA Mauvernay Award

LAUSANNE, Switzerland, Oct. 4, 2021 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categ...

2021-10-04 15:00 1257

New Research in Kosovo Highlights Connection Between Children's Poor Vision and Learning and Development

Study underscores link between uncorrected poor vision and children's potential DALLAS, Oct. 4, 2021 /PRNewswire/ -- A new study, a collaboration of  the Vision Impact Institute, EdGuard Institute, and ESSILOR's Vision for Life™ social impact fund, offers new insight into the correlation between ...

2021-10-04 12:30 1518

Chiranya Prachaseri recognized as Asia's Most Inspiring Executives

BANGKOK, Oct. 4, 2021 /PRNewswire/ -- "As recognized by the ACES Awards 2021 for theAsia's Most Inspiring Executives award, it is such a great honor not only me but also everyone in Cryoviva for being a team player and builder together", said Chiranya Prachaseri, Chief Executive Officer of Cryovi...

2021-10-04 10:30 2292

Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021

DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences  Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health ...

2021-10-04 08:00 3074

Colorectal cancer diagnoses dropped over 40% during COVID-19 pandemic, new study shows

VIENNA, Oct. 4, 2021 /PRNewswire/ -- The number of colorectal cancer (CRC) cases diagnosed fell dramatically by 40% in a year during the COVID-19 pandemic, new research presented today at UEG Week Virtual 2021 has shown. The research, which was conducted across multiple hospitals in Spain, compa...

2021-10-04 06:00 1778

In Lead-up to Breast Cancer Awareness Month, New Hologic Global Women's Health Index Finds Globally Most Women Were Not Checked for Any Cancer in Past Year

Worldwide, 88% of women said in 2020 that they had not been tested for any type of cancer in the past 12 months. Most women believe checkups help improve health, but 40% haven't talked to a healthcare professional in the past 12 months. WASHINGTON, Oct. 2, 2021 /PRNewswire/ -- In the lead-up to ...

2021-10-02 12:18 3201

World's Leading Neuroscientists Unveil Research on COVID-19's Impact on the Brain, Understanding Migraine Pathophysiology, Solving the Mystery of Sleep, Biomarkers in Traumatic Brain Injury and More at 25th Biennial World Congress of Neurology from October 3-7

LONDON, Oct. 2, 2021 /PRNewswire/ -- The impact COVID-19 has on the brain, understanding migraine pathophysiology, solving the mystery of sleep by "Lighting Up the Brain," blood biomarkers for traumatic brain injury and more groundbreaking research will be unveiled by the world's leading neurosci...

2021-10-02 12:10 4404

CStone presents ARROW study data for GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer (MTC) for the first time in a late breaking oral abstract session at the 90th Annual Meeting of the American Thyroid Association 2021

* Primary efficacy results showed GAVRETO had robust and durable anti-tumor activity in the Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), with a confirmed objective response rate (ORR) of 73.1%. And the 9-month duration of response (DOR) rate was 100% ...

2021-10-02 08:30 8862
1 ... 322323324325326327328 ... 572

Week's Top Stories